Common use of Regulatory Submission Clause in Contracts

Regulatory Submission. At the appropriate time, Scopus Biopharma plans to file a pre-IND meeting request with FDA to confirm that the planned CMC and non-clinical tasks will support the initiation of the proposed Phase 1 clinical trials. In this way, course corrections in the development plan can be made early on, expediting development and avoiding waste of resources.

Appears in 2 contracts

Sources: Research and License Agreement (Scopus BioPharma Inc.), Research and License Agreement (Scopus BioPharma Inc.)